counter-ion raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Inframammary incision: The plastic surgeon makes a long cut at the inframammary fold (IMF) — the bottom border of the breast — for maximal access to the interior of the breast hemisphere. The inframammary incision allows for the precise cutting of tissues in order to securely emplace the prosthetic breast into the implant-pocket cut into the chest muscle. Moreover, according to the skin-type of the woman, the emplacement of a prosthetic breast by way of an IMF-incision can result in noticeable surgical scars. Periareolar incision: The surgeon makes a short incision (5.0 cm.) along the areolar periphery (outside border of the areola) which allows for the symmetrical adjustment of the position of the inframammary fold (IMF) of the augmented breast. The periareolar incision is made at the medial-half (bottom half) of the outside border of the nipple-areola complex (NAC) of the breast to be augmented. Given the narrow access allowed into the skin-envelope of the breast hemisphere, the short, five-centimetre length of the periareolar incision makes difficult the surgeon's emplacement of a voluminous breast-implant made of silicone gel. Moreover, as a surgical approach, the periareolar incision (cutting along the outside border of the NAC) allows the plastic surgeon to also do a breast-lift procedure that has been included to an initial, primary mammoplasty procedure.
==== Vaso-occlusive crisis ==== Also termed "sickle cell crisis" or "sickling crisis", the vaso-occlusive crisis (VOC) manifests principally as extreme pain, most often affecting the chest, back, legs, and/or arms. The underlying cause is sickle-shaped red blood cells that obstruct capillaries and restrict blood flow to an organ, resulting in ischaemia, pain, necrosis, and often organ damage. The frequency, severity, and duration of these crises vary considerably. Milder crises can be managed with nonsteroidal anti-inflammatory drugs. For more severe crises, patients may require inpatient management for intravenous opioids. Vaso-occlusive crisis involving organs such as the lungs or the penis are considered an emergency and treated with red blood cell transfusions. A VOC can be triggered by anything which causes blood vessels to constrict; this includes physical or mental stress, cold, and dehydration. "After Haemoglobin S (HbS) deoxygenates in the capillaries, it takes some time (seconds) for HbS polymerization and the subsequent flexible-to-rigid transformation. If the transit time of RBC through the microvasculature is longer than the polymerization time, sickled RBC will lodge in the microvasculature."
==== Non-state actors ==== United Nations: The UN urged de-escalation between the belligerents and urged measures to protect civilians. European Union: The EU urged de-escalation and the implementation of the ceasefire declared on 15 July. It expressed its concern over Syria's sovereignty and integrity. Arab League: The General Secretariat of the Arab League strongly condemned the Israeli airstrikes on Syria, describing them as a blatant violation of the sovereignty of a fellow Arab League and UN member state and a clear breach of international law. The League characterized the attacks as acts of "bullying" that must not be tolerated by the regional or international community and called for their immediate cessation. It warned that the strikes aimed to sow chaos in Syria by exploiting recent unrest in Suwayda—events which the Syrian government itself denounced and pledged to investigate. The League expressed full solidarity with Syria, urging the government to defuse tensions through dialogue and inclusive national reconciliation. Gulf Cooperation Council: The council condemned Israeli attacks on Syria. The Muslim World League issued a statement expressing its full solidarity with Syria against any threats to its security, stability, and sovereignty, particularly attempts to sow discord among its communities or interfere in its internal affairs. The League voiced support for the Syrian government's efforts to protect all segments of the population, uphold civil peace, and enforce the rule of law.
=== Belgium === In Belgium, a clinical biologist (biologiste clinique) is a medical doctor or pharmacist who has completed a five-year postgraduate specialization in clinical biology (biologie clinique). This specialization is regulated by the Belgian Ministry of Public Health, and clinical biologists work in both hospital and private laboratories. Their training includes rotations in different laboratory disciplines, including hematology, microbiology, and clinical chemistry. They are responsible for interpreting laboratory results, ensuring quality control, and advising clinicians on diagnostic strategies.
For example, a "bisubstrate analog" inhibits kinase action by binding both the conserved ATP binding pocket and a protein/peptide recognition site on the specific kinase. Research groups also utilized ATP analogs as chemical probes to study kinases and identify their substrates. The development of novel chemical means of incorporating phosphomimetic amino acids into proteins has provided important insight into the effects of phosphorylation events. Phosphorylation events have typically been studied by mutating an identified phosphorylation site (serine, threonine or tyrosine) to an amino acid, such as alanine, that cannot be phosphorylated. However, these techniques come with limitations and chemical biologists have developed improved ways of investigating protein phosphorylation. By installing phospho-serine, phospho-threonine or analogous phosphonate mimics into native proteins, researchers are able to perform in vivo studies to investigate the effects of phosphorylation by extending the amount of time a phosphorylation event occurs while minimizing the often-unfavorable effects of mutations. Expressed protein ligation, has proven to be successful techniques for synthetically producing proteins that contain phosphomimetic molecules at either terminus. In addition, researchers have used unnatural amino acid mutagenesis at targeted sites within a peptide sequence. Advances in chemical biology have also improved upon classical techniques of imaging kinase action.
Sources: en.wikipedia.org
From measurements and based on the positions of the footprints, the animal was believed to be traveling at a walking speed of around 2.8 to 5 miles per hour and was estimated to have a hip height of 1.56 to 2.06 m (5.1 to 6.8 ft). A follow-up paper appeared in 2017, increasing the speed estimations by 50–80%. Rare fossil footprints and trackways found in New Mexico and Wyoming that are assigned to the ichnogenus Tyrannosauripus have been attributed to being made by Tyrannosaurus, based on the stratigraphic age of the rocks they are preserved in. The first specimen, found in 1994 was described by Lockley and Hunt and consists of a single, large footprint. Another pair of ichnofossils, described in 2021, show a large tyrannosaurid rising from a prone position by rising up using its elbows in conjunction with the pads on their feet to stand. These two unique sets of fossils were found in Ludlow, Colorado and Cimarron, New Mexico. Another ichnofossil described in 2018, perhaps belonging to a juvenile Tyrannosaurus or Nanotyrannus was uncovered in the Lance Formation of Wyoming. The trackway itself offers a rare glimpse into the walking speed of tyrannosaurids, and the trackmaker is estimated to have been moving at a speed of 4.5–8.0 kilometers per hour (2.8–5.0 mph), significantly faster than previously assumed for estimations of walking speed in tyrannosaurids.
=== Cystinosis === Mutations in CTNS gene can result in cystinosis. Cystinosis is a type of lysosomal transport disorder, a subset of lysosomal storage disorders. Variation in the encoded cystinosin protein results in an inhibition or loss in its ability to transport cystine out of the lysosome. Cystine molecules accumulate and form crystals within the lysosome, impairing its function.
Abbi Jacobson as Shira Schwooper, the middle of the Schwooper children, and sole daughter of Naomi and Elliot. Born in August 1984, Shira is a lesbian and is married to Kendra, with whom she raises twin boys, Walter and Benjamin, and lives in Oakland, California. Shira is blunt, sardonic, stubborn, and easily holds grudges, but she’s nonetheless still compassionate and loves her family, and has a loving healthy relationship with her wife. As a child, Shira was best friends with Rachel "Baby" Feldstein, and had a romantic relationship with Rachel in high school. However, after catching her making out with a man, Shira discovers Rachel saw her as a fling and feels betrayed, which ends their friendship. Shira cannot conceive children due to primary ovarian insufficiency, so Kendra bears the couple's children. Nicole Byer as Kendra Hooper, a lesbian and Shira's wife, who converts to Judaism as an adult after lying about being Jewish to cover up for a work absence during Rosh Hashanah. Born in 1982, Kendra is more grounded than her wife and loves her in spite of her stubborn tendencies. Kendra works as a senior manager for B.J Banana Fingers, a children's entertainment fast-food chain similar to Chuck E. Cheese. She gained her role due to her being a former workaholic who over-exerted herself—a habit she picked up from her father—after being accepted into a managerial training program when she was a floor manager. Kendra fired an employee who helped her as a child in order to gain a higher position by setting her up, which Kendra will have to live with.
=== SPAC merger, public listing, and acquisitions (2020–2023) === In October 2020, Hims announced an agreement to become a publicly traded company through a merger with Oaktree Acquisition Corp., a special-purpose acquisition company led by Oaktree Capital Management co-chairman Howard Marks. The transaction closed on January 20, 2021 at a valuation of $1.6 billion, and shares began trading the following day on the New York Stock Exchange. The deal provided the company with about $280 million in proceeds, including $75 million from private placement investors such as Franklin Templeton Investments. In June 2021, Hims & Hers acquired London-based Honest Health Limited, marking its first international acquisition and expanding its United Kingdom operations. The following month, the company acquired the teledermatology platform Apostrophe (YoDerm, Inc.) for potential consideration of up to $200 million. Apostrophe was shut down in 2025.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.